Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

BACKGROUND: A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly observed; however, how tumor heterogeneity is reflected in indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Skaga, Erlend, Kulesskiy, Evgeny, Fayzullin, Artem, Sandberg, Cecilie J., Potdar, Swapnil, Kyttälä, Aija, Langmoen, Iver A., Laakso, Aki, Gaál-Paavola, Emília, Perola, Markus, Wennerberg, Krister, Vik-Mo, Einar O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593575/
https://www.ncbi.nlm.nih.gov/pubmed/31238897
http://dx.doi.org/10.1186/s12885-019-5861-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593575/
https://www.ncbi.nlm.nih.gov/pubmed/31238897
http://dx.doi.org/10.1186/s12885-019-5861-4

Ejemplares similares